Table 1.
Demographic characteristics and the type of SARS-CoV-2 vaccination of patients with autoimmune and inflammatory RMDs and healthy controls.
| Age, years | Female | Disease duration, years | BBIBP-CorV | Gam-Covid-Vac | AZD1222 | BNT162b2 | mRNA-1273 | |
|---|---|---|---|---|---|---|---|---|
| Controls, n = 74 | 43 ± 12.5 | 46 (62%) | – | 18 (24%) | 16 (22%) | 14 (19%) | 16 (22%) | 10 (13%) |
| All patients with aiRMDs, n = 89 | 59 ± 14 | 64 (72%) | 11 ± 8.4 | 11 (12%) | 8 (9%) | 20 (22%) | 34 (39%) | 16 (18%) |
| RA, n = 41 | 62 ± 10.1 | 33 (83%) | 12 ± 9.1 | 6 (15%) | 5 (12%) | 8 (19%) | 20 (49%) | 2 (5%) |
| PsA, n = 7 | 50 ± 6.6 | 4 (57%) | 9 ± 6.6 | 0 | 1 (14%) | 1 (14%) | 2 (29%) | 3 (43%) |
| AxSpa, n = 12 | 48 ± 14.1 | 1 (8%) | 13 ± 10.2 | 2 (17%) | 0 | 1 (8%) | 4 (33%) | 5 (42%) |
| SLE n = 11 | 52 ± 14.1 | 1 (9%) | 13 ± 9.4 | 0 | 1 (9%) | 3 (27%) | 4 (37%) | 3 (27%) |
| SS n = 4 | 62 ± 12 | 4 (100%) | 9 ± 3.9 | 1 (25%) | 0 | 2 (50%) | 1 (25%) | 0 |
| IIM n= 1 | 75 | 1 (100%) | 6 | 0 | 0 | 0 | 1 (100%) | 0 |
| SSc n = 1 | 73 | 1 (100%) | 3 | 0 | 0 | 0 | 1 (100%) | 0 |
| LVV, n = 5 | 70 ± 6.3 | 4 (80%) | 4 ± 3.3 | 1 (20%) | 0 | 0 | 2 (40%) | 2 (40%) |
| AAV, n = 6 | 69 ± 11 | 4 (67%) | 8 ± 2.9 | 0 | 1 (17%) | 1 (17%) | 3 (50%) | 1 (17%) |
| Other vasculitis, n = 1 | 54 | 1 (100%) | 13 | 0 | 0 | 1 (100%) | 0 | 0 |
Data are presented as mean ± SD or n (%). AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; aiRMD, autoimmune and inflammatory rheumatic and musculoskeletal disease; AxSpA, axial spondyloarthritis; IIM, idiopathic inflammatory myositis; LVV, large vessel vasculitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus, SS, Sjögren syndrome; SSc, systemic sclerosis.